Abstract
Dementia is one of the main causes of the disease burden in developed regions. According to the World Health Organization (WHO), it will become the world’s second leading cause of death by the middle of the century, overtaking cancer. This will have a dramatic impact on medical care, and have important social and economic implications, unless more effective preventive procedures or treatments become available. Alzheimer’s disease (AD) is the most common cause of dementia, accounting for approximately 50–75% of all dementias worldwide, followed by vascular dementia, mixed dementia, and Lewy body dementia.
Currently, acetylcholinesterase (AChE) inhibitors, such as donepezil, rivastigmine and galantamine are used to treat mild to moderate AD. An alternative therapy for severe AD is memantine, an antagonist of the NMDA-subtype of glutamate receptors. However, these drugs provide only temporary symptom improvement, and do not alter disease progression, except temporarily in some patients.
In recent years different approaches have been developed to provide a more effective treatment for AD. These approached include the discovery of emerging targets and new drugs aiming at a single target, but given the complexity of the disease, different targets may need to be engaged simultaneously. New strategies have explored bitopic inhibitors, for example a single drug that acts on different sites of the acetylcholinesterase enzyme to produce at least two different activities, and multitarget drugs that act on multiple therapeutic targets.
In this review, we explore the journey from a bitopic inhibitor strategy to multitarget drugs for the future treatment of AD.
Keywords: AChE, Alzheimer’s disease, BACE-1, bitopic drugs, BuChE, cannabinoids, GSK3β, multitarget.
Current Medicinal Chemistry
Title:From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease
Volume: 22 Issue: 33
Author(s): Daniel I. Perez, Ana Martinez, Carmen Gil and Nuria E. Campillo
Affiliation:
Keywords: AChE, Alzheimer’s disease, BACE-1, bitopic drugs, BuChE, cannabinoids, GSK3β, multitarget.
Abstract: Dementia is one of the main causes of the disease burden in developed regions. According to the World Health Organization (WHO), it will become the world’s second leading cause of death by the middle of the century, overtaking cancer. This will have a dramatic impact on medical care, and have important social and economic implications, unless more effective preventive procedures or treatments become available. Alzheimer’s disease (AD) is the most common cause of dementia, accounting for approximately 50–75% of all dementias worldwide, followed by vascular dementia, mixed dementia, and Lewy body dementia.
Currently, acetylcholinesterase (AChE) inhibitors, such as donepezil, rivastigmine and galantamine are used to treat mild to moderate AD. An alternative therapy for severe AD is memantine, an antagonist of the NMDA-subtype of glutamate receptors. However, these drugs provide only temporary symptom improvement, and do not alter disease progression, except temporarily in some patients.
In recent years different approaches have been developed to provide a more effective treatment for AD. These approached include the discovery of emerging targets and new drugs aiming at a single target, but given the complexity of the disease, different targets may need to be engaged simultaneously. New strategies have explored bitopic inhibitors, for example a single drug that acts on different sites of the acetylcholinesterase enzyme to produce at least two different activities, and multitarget drugs that act on multiple therapeutic targets.
In this review, we explore the journey from a bitopic inhibitor strategy to multitarget drugs for the future treatment of AD.
Export Options
About this article
Cite this article as:
Perez I. Daniel, Martinez Ana, Gil Carmen and Campillo E. Nuria, From Bitopic Inhibitors to Multitarget Drugs for the Future Treatment of Alzheimer’s Disease, Current Medicinal Chemistry 2015; 22 (33) . https://dx.doi.org/10.2174/0929867322666150812145825
DOI https://dx.doi.org/10.2174/0929867322666150812145825 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PACAP and Its Receptors Exert Pleiotropic Effects in The Nervous System by Activating Multiple Signaling Pathways
Current Protein & Peptide Science Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Current Pharmaceutical Analysis The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Current Drug Targets Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Molecular Modeling Studies of ABC Transporters Involved in Multidrug Resistance
Mini-Reviews in Medicinal Chemistry The Role of Components of the Lymphoreticular System in Transmissible Spongiform Encephalopathy Pathogenesis and Neuroinvasion
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease
Current Alzheimer Research Vasoactive Intestinal Peptide Receptors: A Molecular Target in Breast and Lung Cancer
Current Pharmaceutical Design ER Stress and Autophagy
Current Molecular Medicine FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus
Current Neurovascular Research Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery